Genmab — Januar 2024
-
Genmab handles pænt op i US . Lige nu i niveau 2224.
-
JPM24: Johnson & Johnson CEO says Tecvayli, Talvey and several other meds are set to trounce analyst estimates https://www.fiercepharma.com/pharma/jpm24-johnson-johnson-ceo-says-tecvayli-talvey-and-several-other-meds-can-vastly-outperform
-
Godmorgen
-
According to Cramer, health-care companies can yield bigger percentage gains than tech companies, for which investors should be looking. He also pointed out the large number of multibillion-dollar biopharma acquisitions announced at the end of 2023, saying investors should be on the lookout for more industry mergers.
9/1 2024 07:03 af Darvin
“Don’t forget that what we care about is percentage gains, not incremental gains,” he said. “And I think we can find bigger percentage gains in health care -
Tirsdagens danske avisuddrag med Vestas, Pandora og Genmab https://www.proinvestor.com/investornyt/1100847/tirsdagens-danske-avisuddrag-med-vestas-pandora-og-genmab
-
Kursmålet for Genmab sænkes med 14 pct. af canadisk finanshus https://www.proinvestor.com/investornyt/1100852/kursmalet-for-genmab-saenkes-med-14-pct-af-canadisk-finanshus
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind